Spectrum Pharmaceuticals Inc (SPPI)

7.65
0.21 2.70
NASDAQ : Health Care
Prev Close 7.86
Open 7.85
Day Low/High 7.63 / 7.89
52 Wk Low/High 4.14 / 7.74
Volume 206.24K
Avg Volume 848.60K
Exchange NASDAQ
Shares Outstanding 80.44M
Market Cap 637.92M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.

Spectrum Pharmaceuticals Highlights Preclinical Data Of ROLONTIS™ (eflapegrastim) At The American Association For Cancer Research (AACR) Annual Meeting

Spectrum Pharmaceuticals Highlights Preclinical Data Of ROLONTIS™ (eflapegrastim) At The American Association For Cancer Research (AACR) Annual Meeting

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the presentation of preclinical...

Spectrum Pharmaceuticals Highlights Three Abstracts On ROLONTIS™ (eflapegrastim) And BELEODAQ® (belinostat) For Injection At The American Association For Cancer Research (AACR) Annual Meeting In Washington, D.C., April 1-5, 2017

Spectrum Pharmaceuticals Highlights Three Abstracts On ROLONTIS™ (eflapegrastim) And BELEODAQ® (belinostat) For Injection At The American Association For Cancer Research (AACR) Annual Meeting In Washington, D.C., April 1-5, 2017

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Spectrum Pharmaceuticals Announces Initiation Of A Phase 2 Trial Of Poziotinib In Non-Small Cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutations

Spectrum Pharmaceuticals Announces Initiation Of A Phase 2 Trial Of Poziotinib In Non-Small Cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutations

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that the University of...

First Week Of November 17th Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week Of November 17th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the November 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Spectrum Pharmaceuticals, BioCryst Pharmaceuticals and Curis were among the biotech stock movers in premarket trading on Thursday.

Spectrum Pharmaceuticals Reports Fourth Quarter 2016 And Full Year 2016 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2016 And Full Year 2016 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

First Week of SPPI April 21st Options Trading

First Week of SPPI April 21st Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new April 21st contracts and identified the following call contract of particular interest.

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 RBC Capital Markets Global Healthcare Conference On February 23rd

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 RBC Capital Markets Global Healthcare Conference On February 23rd

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Commit To Purchase Spectrum Pharmaceuticals At $3, Earn 16.6% Annualized Using Options

Commit To Purchase Spectrum Pharmaceuticals At $3, Earn 16.6% Annualized Using Options

Investors eyeing a purchase of Spectrum Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.47/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $3 strike, which has a bid at the time of this writing of 20 cents.

Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib In Lung Cancer At The 17th IASLC World Conference On Lung Cancer

Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib In Lung Cancer At The 17th IASLC World Conference On Lung Cancer

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced the oral presentation of data...

Spectrum Pharmaceuticals Highlights Survival Advantage In A Case Match Control Analysis Of The PROPEL Study With FOLOTYN® (pralatrexate Injection) at The 58th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals Highlights Survival Advantage In A Case Match Control Analysis Of The PROPEL Study With FOLOTYN® (pralatrexate Injection) at The 58th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced the presentation of data from a...

Spectrum Pharmaceuticals Highlights Five Abstracts On ROLONTIS™ (eflapegrastim) And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS) In San Antonio, Texas, December 6-10, 2016

Spectrum Pharmaceuticals Highlights Five Abstracts On ROLONTIS™ (eflapegrastim) And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS) In San Antonio, Texas, December 6-10, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Spectrum Pharmaceuticals Highlights Four Abstracts At The 58th Annual Meeting Of The American Society Of Hematology (ASH) In San Diego, California, December 3-6, 2016

Spectrum Pharmaceuticals Highlights Four Abstracts At The 58th Annual Meeting Of The American Society Of Hematology (ASH) In San Diego, California, December 3-6, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.

Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  November 21, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

Spectrum Pharmaceuticals Announces Poziotinib Data Presentation At The 17th IASLC World Conference On Lung Cancer In Vienna, Austria, December 4-7, 2016

Spectrum Pharmaceuticals Announces Poziotinib Data Presentation At The 17th IASLC World Conference On Lung Cancer In Vienna, Austria, December 4-7, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that scientists from MD...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Spectrum Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of November 21, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Spectrum Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of November 21, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc.

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals Provides Third Quarter Financial Update

Spectrum Pharmaceuticals Provides Third Quarter Financial Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced today financial results for...

SPPI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Shareholders Of A Class Action Involving Spectrum Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of November 21, 2016

SPPI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Shareholders Of A Class Action Involving Spectrum Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of November 21, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Nevada on behalf of investors who purchased Spectrum Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals Provides Third Quarter Financial And Pipeline Update

Spectrum Pharmaceuticals Provides Third Quarter Financial And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced that the earnings...

GPM Reminds Investors Of The November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the November 21, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

Tax-Loss Selling Offers Stock-Picking Opportunities

Our screen reveals 17 names that could become oversold and disconnected from their fundamentals as a result of this phenomenon.

Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...